Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants
These data support that, considering its large therapeutic window, asciminib 200 mg twice daily can be used without any dose adjustment when co-administered with a strong CYP3A4 inducer drug. Furthermore, asciminib is not an OATP1B inhibitor up to this dose.
Authors
- Athiná Kranidi
- Annie St. Pierre
- Felix Huth (ORCID: https://orcid.org/0000-0002-7121-4394)
- Ioannis Loisios-Konstantinidis (ORCID: https://orcid.org/0000-0003-2586-3577)
- Michelle Quinlan
- Seshulatha Jamalapuram
- Noemi Espurz
- Matthias Hoch (ORCID: https://orcid.org/0009-0005-1033-2716)
- Amanda Taylor
- Suleyman Eralp Bellibas
- David Coleman
Institutions
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- Novartis (Ireland) (IE)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1007/s40262-026-01629-1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00